ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,167.37
0.00%
Dow Jones
40,358.09
-0.14%
Gold vs US Dollar
2,415.83
0.29%
Brent Oil
80.605
-0.21%
Bitcoin
65,904.83
-0.03%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
24/07/202407:55PR Newswire (US)Opulent Maritime Selects ADP Clear to Digitize its Bunkering Operations
24/07/202407:55UK RegulatoryOSE Immunotherapeutics annonce des résultats positifs d'efficacité de Lusvertikimab dans l'essai clinique de phase 2 pour le traitement de la rectocolite hémorragiqueTG:6OPOSE Immunotherapeutics
24/07/202407:55UK RegulatoryOSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative ColitisLSE:0RADOse Immunotherapeutics Sa
24/07/202407:55UK RegulatoryOSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative ColitisTG:6OPOSE Immunotherapeutics
24/07/202407:55UK RegulatoryOSE Immunotherapeutics annonce des résultats positifs d'efficacité de Lusvertikimab dans l'essai clinique de phase 2 pour le traitement de la rectocolite hémorragiqueLSE:0RADOse Immunotherapeutics Sa
24/07/202407:55UK RegulatoryOSE Immunotherapeutics annonce des résultats positifs d'efficacité de Lusvertikimab dans l'essai clinique de phase 2 pour le traitement de la rectocolite hémorragiqueEU:OSEOSE Immunotherapeutics
24/07/202407:55UK RegulatoryOSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative ColitisEU:OSEOSE Immunotherapeutics
24/07/202407:51Alliance NewsAlliance NewsLONDON BRIEFING: Reckitt to simplify; Informa agrees Ascential buy
24/07/202407:50PR Newswire (US)2024 Surge in Demand for Trending Collectibles: Collectibles Industry Valued at $601.2 Billion in 2024 with 9.2% Annual Growth: Report by Market Decipher
24/07/202407:45PR Newswire (US)2024 Surge in Demand for Trending Collectibles: Collectibles Industry Valued at $601.2 Billion in 2024 with 9.2% Annual Growth: Report by Market Decipher
24/07/202407:39UK RegulatoryCorrection: Harju Elekter Group financial results, 1-6/2024LSE:0MDUHarju Elekter As
24/07/202407:30UK RegulatoryAVAILABILITY OF THE FINANCIAL REPORT FOR THE FIRST HALF OF 2024BIT:1FRVIAForvia SE
24/07/202407:30UK RegulatoryMise à disposition du Rapport financier du premier semestre 2024BIT:1FRVIAForvia SE
24/07/202407:30UK RegulatoryMise à disposition du Rapport financier du premier semestre 2024EU:FRVIAForvia SE
24/07/202407:30UK RegulatoryAVAILABILITY OF THE FINANCIAL REPORT FOR THE FIRST HALF OF 2024BIT:EOFaurecia SE
24/07/202407:30UK RegulatoryMise à disposition du Rapport financier du premier semestre 2024BIT:1EOFaurecia SE
24/07/202407:30UK RegulatoryMise à disposition du Rapport financier du premier semestre 2024TG:FAUForvia SE
24/07/202407:30UK RegulatoryAVAILABILITY OF THE FINANCIAL REPORT FOR THE FIRST HALF OF 2024BIT:1EOFaurecia SE
24/07/202407:30UK RegulatoryMise à disposition du Rapport financier du premier semestre 2024BIT:EOFaurecia SE
24/07/202407:30UK RegulatoryAVAILABILITY OF THE FINANCIAL REPORT FOR THE FIRST HALF OF 2024TG:FAUForvia SE
24/07/202407:30UK RegulatoryAVAILABILITY OF THE FINANCIAL REPORT FOR THE FIRST HALF OF 2024EU:FRVIAForvia SE
24/07/202407:23PR Newswire (US)SM Marks 30 Years of Real Estate Innovation and Growth
24/07/202407:21UK RegulatoryAtos - Point de Marché du 24 juillet 2024TG:AXIAtos SE
24/07/202407:21UK RegulatoryAtos Market Update – July 24, 2024EU:ATOAtos SE
24/07/202407:21UK RegulatoryAtos Market Update – July 24, 2024TG:AXIAtos SE
24/07/202407:21UK RegulatoryAtos - Point de Marché du 24 juillet 2024EU:ATOAtos SE
24/07/202407:03EQS Regulatory NewsSWEF: Portfolio UpdateLSE:SWEFStarwood European Real Estate Finance Limited
24/07/202407:03UK RegulatoryFidelity SR Enh Japan Eq ETF - Net Asset Value(s)LSE:FJPRFid Sre Jp Etf
24/07/202407:03UK RegulatoryFidelity Global Quality Income $ Inc FGQI - Net Asset Value(s)LSE:FGQIGblqtyincusdinc
24/07/202407:03UK RegulatoryFidelity US Quality Income $ Acc FUSA - Net Asset Value(s)LSE:FUSAUsqtyincusdacc

Your Recent History

LSE
STX
Shield Therapeutics
LSE
EZJ
Easyjet
LSE
HUM
Hummingbird Resources
LSE
AAZ
Anglo Asian Mining
LSE
OCDO
Ocado
LSE
QBT
Quantum Blockchain Techn...
LSE
VRS
Versarien
LSE
POS
Plexus
LSE
SBTX
Skinbiotherapeutics
LSE
HOC
Hochschild Mining
LSE
SCLP
Scancell
LSE
MIN
Minoan
LSE
SPSY
Spectra Systems
LSE
SWG
Shearwater
LSE
SOLG
Solgold
LSE
GOLD
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved